GlobeImmune Inc (GBIM)

GlobeImmune, Inc. is a biotechnology company whose common stock is listed on OTC Markets under the ticker GBIM. The company focuses on developing therapeutic candidates for cancer and infectious diseases using its proprietary Tarmogen platform. Its pipeline has included GS-4774 for chronic hepatitis B infection, GI-6301 for cancers expressing brachyury, GI-6207 for medullary thyroid cancer, and GI-4000 for several oncology indications, including resected pancreas cancer, non-small cell lung cancer, and colorectal cancer. GlobeImmune also has preclinical infectious disease programs such as GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus infection. The company has reported strategic collaborations with Gilead Sciences and Celgene. Founded in 1995 and headquartered in Louisville, Colorado, it was previously known as Ceres Pharmaceuticals, Inc. and adopted the GlobeImmune name in 2001. GlobeImmune operates as a subsidiary of NantCell, Inc.

Jump directly to the stock analysis sections supported by the latest available data.